- Home
- KNSA vs ADNT Comparison
KNSA vs ADNT Comparison
Compare KNSA & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- ADNT
- Stock Information
- Founded
- KNSA 2015
- ADNT 2016
- Country
- KNSA United Kingdom
- ADNT Ireland
- Employees
- KNSA N/A
- ADNT N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- ADNT Auto Parts:O.E.M.
- Sector
- KNSA Health Care
- ADNT Consumer Discretionary
- Exchange
- KNSA Nasdaq
- ADNT Nasdaq
- Market Cap
- KNSA 1.7B
- ADNT 1.7B
- IPO Year
- KNSA 2018
- ADNT N/A
- Fundamental
- Price
- KNSA $20.59
- ADNT $16.86
- Analyst Decision
- KNSA Strong Buy
- ADNT Hold
- Analyst Count
- KNSA 5
- ADNT 9
- Target Price
- KNSA $36.60
- ADNT $23.50
- AVG Volume (30 Days)
- KNSA 290.2K
- ADNT 1.2M
- Earning Date
- KNSA 10-29-2024
- ADNT 02-05-2025
- Dividend Yield
- KNSA N/A
- ADNT N/A
- EPS Growth
- KNSA N/A
- ADNT N/A
- EPS
- KNSA N/A
- ADNT 0.20
- Revenue
- KNSA $384,098,000.00
- ADNT $14,688,000,000.00
- Revenue This Year
- KNSA $60.05
- ADNT N/A
- Revenue Next Year
- KNSA $36.32
- ADNT $0.91
- P/E Ratio
- KNSA N/A
- ADNT $84.25
- Revenue Growth
- KNSA 54.41
- ADNT N/A
- 52 Week Low
- KNSA $16.56
- ADNT $16.77
- 52 Week High
- KNSA $28.15
- ADNT $37.19
- Technical
- Relative Strength Index (RSI)
- KNSA 40.95
- ADNT 28.07
- Support Level
- KNSA $19.97
- ADNT $18.96
- Resistance Level
- KNSA $20.85
- ADNT $18.06
- Average True Range (ATR)
- KNSA 0.69
- ADNT 0.84
- MACD
- KNSA 0.03
- ADNT -0.23
- Stochastic Oscillator
- KNSA 35.61
- ADNT 2.31
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion.